Literature DB >> 33401946

Mitigation of Rebound Hyperglycemia With Real-Time Continuous Glucose Monitoring Data and Predictive Alerts.

Giada Acciaroli1, John B Welsh1, Halis Kaan Akturk2.   

Abstract

BACKGROUND: Excess carbohydrate intake during hypoglycemia can lead to rebound hyperglycemia (RH). We investigated associations between RH and use of real-time continuous glucose monitoring (rtCGM) and an rtCGM system's predictive alert.
METHODS: RH events were series of sensor glucose values (SGVs) >180 mg/dL starting within two hours of an antecedent SGV <70 mg/dL. Events were characterized by their frequency, duration (consecutive SGVs >180 mg/dL × five minutes), and severity (area under the glucose concentration-time curve). To assess the impact of rtCGM, data gathered during the four-week baseline phase (without rtCGM) and four-week follow-up phase (with rtCGM) from 75 participants in the HypoDE clinical trial (NCT02671968) of hypoglycemia-unaware individuals were compared. To assess the impact of predictive alerts, we identified a convenience sample of 24 518 users of an rtCGM system without predictive alerts who transitioned to a system whose predictive alert signals an SGV ≤55 mg/dL within 20 minutes (Dexcom G5 and G6, respectively). RH events from periods of blinded versus unblinded rtCGM wear and from periods of G5 and G6 wear were compared with paired t tests.
RESULTS: Compared to RH events in the HypoDE baseline phase, the mean frequency, duration, and severity of events fell by 14%, 12%, and 23%, respectively, in the follow-up phase (all P < .05). Compared to RH events during G5 use, the mean frequency, duration, and severity of events fell by 7%, 8%, and 13%, respectively, during G6 use (all P < .001).
CONCLUSIONS: Rebound hypreglycemia can be objectively quantified and mitigated with rtCGM and rtCGM-based predictive alerts.

Entities:  

Keywords:  HypoDE; continuous glucose monitoring; glucose variability; predictive alerts; real-world analysis; rebound hyperglycemia

Mesh:

Substances:

Year:  2021        PMID: 33401946      PMCID: PMC9294577          DOI: 10.1177/1932296820982584

Source DB:  PubMed          Journal:  J Diabetes Sci Technol        ISSN: 1932-2968


  22 in total

1.  Experimental non-severe hypoglycaemia substantially impairs cognitive function in type 2 diabetes: a randomised crossover trial.

Authors:  Malin Nilsson; Nicole Jensen; Michael Gejl; Marianne L Bergmann; Heidi Storgaard; Mette Zander; Kamilla Miskowiak; Jørgen Rungby
Journal:  Diabetologia       Date:  2019-07-31       Impact factor: 10.122

2.  Assessment of Glucose Control Metrics by Discriminant Ratio.

Authors:  Vanessa Moscardó; Pau Herrero; Monika Reddy; Nathan R Hill; Pantelis Georgiou; Nick Oliver
Journal:  Diabetes Technol Ther       Date:  2020-10       Impact factor: 6.118

Review 3.  Glycaemic variability in diabetes: clinical and therapeutic implications.

Authors:  Antonio Ceriello; Louis Monnier; David Owens
Journal:  Lancet Diabetes Endocrinol       Date:  2018-08-13       Impact factor: 32.069

4.  Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study.

Authors:  Jan Šoupal; Lenka Petruželková; George Grunberger; Aneta Hásková; Milan Flekač; Martin Matoulek; Ondřej Mikeš; Tomáš Pelcl; Jan Škrha; Eva Horová; Jan Škrha; Christopher G Parkin; Štěpán Svačina; Martin Prázný
Journal:  Diabetes Care       Date:  2019-09-17       Impact factor: 19.112

5.  HypoDE: Research Design and Methods of a Randomized Controlled Study Evaluating the Impact of Real-Time CGM Usage on the Frequency of CGM Glucose Values <55 mg/dl in Patients With Type 1 Diabetes and Problematic Hypoglycemia Treated With Multiple Daily Injections.

Authors:  Lutz Heinemann; Dorothee Deiss; Norbert Hermanns; Claudia Graham; Matthias Kaltheuner; Andreas Liebl; David Price
Journal:  J Diabetes Sci Technol       Date:  2015-03-09

6.  Subcutaneous administration of glargine to diabetic patients receiving insulin infusion prevents rebound hyperglycemia.

Authors:  Elisa Hsia; Stacey Seggelke; Joanna Gibbs; R Matthew Hawkins; Elizabeth Cohlmia; Neda Rasouli; Cecilia Wang; Igal Kam; Boris Draznin
Journal:  J Clin Endocrinol Metab       Date:  2012-06-08       Impact factor: 5.958

7.  Associations of serum glucagon levels with glycemic variability in type 1 diabetes with different disease durations.

Authors:  Ke Li; Wen-Jing Song; Xia Wu; Dan-Yang Gu; Pu Zang; Ping Gu; Bin Lu; Jia-Qing Shao
Journal:  Endocrine       Date:  2018-06-18       Impact factor: 3.633

8.  Improved Real-World Glycemic Control With Continuous Glucose Monitoring System Predictive Alerts.

Authors:  Sinu Bessy Abraham; Siddharth Arunachalam; Alex Zhong; Pratik Agrawal; Ohad Cohen; Chantal M McMahon
Journal:  J Diabetes Sci Technol       Date:  2019-07-04

9.  A Human Randomized Controlled Trial Comparing Metabolic Responses to Single and Repeated Hypoglycemia in Type 1 Diabetes.

Authors:  Mads Bisgaard Bengtsen; Julie Støy; Nikolaj Fibiger Rittig; Thomas Schmidt Voss; Nils Erik Magnusson; Mads Vadsted Svart; Niels Jessen; Niels Møller
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

10.  Impaired glucagon secretion in patients with fulminant type 1 diabetes mellitus.

Authors:  Hisako Komada; Yushi Hirota; Kazuhiko Sakaguchi; Yoko Okuno; Wataru Ogawa; Susumu Seino
Journal:  Endocrine       Date:  2018-09-10       Impact factor: 3.633

View more
  2 in total

1.  Characterization of Post-Hypoglycemic Hyperglycemia in Children and Adolescents With Type 1 Diabetes: The EPHICA Study.

Authors:  Victoria Colinet; Philippe A Lysy
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-27       Impact factor: 6.055

2.  Non-adjunctive continuous glucose monitoring for control of hypoglycaemia (COACH): Results of a post-approval observational study.

Authors:  Stayce E Beck; Colleen Kelly; David A Price
Journal:  Diabet Med       Date:  2021-11-23       Impact factor: 4.213

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.